Medically reviewed by Elizabeth Mbata, MD. Last reviewed July 2026.
Medicinal leeches are a real, regulated medical device used in hospitals today, and they have one narrow job. The FDA cleared them in June 2004 for a single purpose: relieving venous congestion in tissue that has been reattached or transferred in surgery, such as a replanted finger or ear or a reconstructive flap. That use is legitimate and sometimes saves tissue that would otherwise die. Everything else leeches are marketed for, including arthritis, heart disease, varicose veins, and “detoxification,” sits somewhere between preliminary and entirely unevidenced. Here is where the line falls.
The Cleared Medical Use
The FDA cleared medicinal leeches under 510(k) number K040187, with a decision date of 21 June 2004. The indication in the FDA’s own record is specific:
“an adjunct to the graft tissue healing when problems of venous congestion may delay healing, or to overcome the problem of venous congestion by creating prolonged localized bleeding.”
That is the entire cleared indication. Two points of accuracy that most articles get wrong. First, leeches are listed by the FDA as unclassified, a pre-amendment device, not Class II as is widely repeated. Second, regulatory responsibility has transferred from the device centre to the biologics centre, which makes most older writing on their status out of date.
Note also that cleared is not approved. Clearance establishes that a device is substantially equivalent to something already on the market, which is a lower bar than the approval pathway.
What Venous Congestion Is, and Why Leeches Help
When a surgeon reattaches a finger or moves a flap of tissue, arteries and veins both have to be reconnected. Arteries are thick-walled and easier to reconnect. Veins are thin and collapse easily.
If arterial blood flows in but venous blood cannot flow out, the tissue engorges, turns dark and swollen, and dies from the inside out. This can progress within about three hours. Leeches provide a temporary outflow route while the body grows new small vessels.
The mechanism is often misunderstood. The benefit is not mainly the small amount of blood the leech drinks. Leech saliva contains hirudin, a direct thrombin inhibitor, along with a platelet aggregation inhibitor, an enzyme that helps those compounds spread, a vasodilator, and a local anaesthetic that makes the bite largely painless. The result is that the bite site keeps oozing for hours after the leech detaches, and that sustained decompression is the treatment.
How Well It Works
Honestly reported, results vary a great deal and this is a salvage measure rather than a reliable rescue.
Published tissue salvage rates range from roughly 61% to 78%. A two-year single-centre review found 65% overall, but the breakdown matters: 100% for pedicled flaps and 77% for flaps generally, against 43% for digits overall and 25% for digital replants. Those subgroups are small, so they should not be read as definitive, but a page that quotes only the 78% figure is overselling the treatment.
The Risks Are Real
Infection is the dominant one. A bacterium called Aeromonas hydrophila lives in the leech gut, where it helps digest blood. It cannot be eliminated without killing the leech, so this is an intrinsic hazard rather than a hygiene failure. Reported infection rates range widely across sources, roughly 2% to 36%.
Because of this, preventive antibiotics are standard and effectively mandatory, usually ciprofloxacin or trimethoprim-sulfamethoxazole. There is a current complication: ciprofloxacin-resistant Aeromonas infections after leech therapy have been reported in the US, Canada, and France since 2011. The mechanism is striking, in that the leech gut itself contains low-level antimicrobials that select for resistant organisms. Some centres now culture leech water on delivery and choose antibiotics from susceptibility results.
Blood loss is substantial. In one series of head and neck flap patients, every patient required a blood transfusion, with a median of 13.5 units of packed red cells and treatment running a median of nine days. That series involved severely compromised flaps and is likely at the worse end, but it establishes that this is inpatient therapy with serious consequences, monitored with blood counts every eight hours.
Allergic reactions including anaphylaxis have been reported.
Leeches are single use. After treating one patient a leech is euthanised and disposed of as medical waste. Reusing one across patients would be a direct route for blood-borne transmission.
Contraindications include poor arterial supply to the area, immunosuppression, bleeding disorders such as haemophilia, refusal of transfusion, and previous leech allergy. A patient with undiagnosed arterial disease developed septic gangrene after leech therapy, which is why proper assessment matters.
Why Medical-Grade Sourcing Is Not Optional
Clinical leeches come from purpose-built aquaculture, are starved to a defined interval, kept in monitored water, and supplied against an FDA clearance.
Wild-caught or bait-shop leeches carry unknown species identity, unmonitored gut bacteria, possible parasites, and, critically, residual blood from a previous unknown host. That is a direct blood-borne pathogen route. This is the single most important safety point for anyone who has encountered leech therapy outside a hospital.
The Other Claims
Knee osteoarthritis is the only non-cleared use with genuine trial evidence, and it deserves to be reported fairly rather than dismissed. Meta-analyses of four randomised trials covering about 264 patients found significant improvements in pain and function scores at one, four, and seven weeks, with evidence quality rated moderate. The same analyses found a significantly higher rate of adverse events in the leech groups and called for better trials.
The honest reading: a positive signal from a small total sample, with a serious unresolved problem in that you cannot blind a patient to whether leeches were applied to their knee, and pain is a subjective endpoint. This is not an FDA-cleared use and does not appear in mainstream osteoarthritis guidelines. Preliminary, not established.
Cardiovascular disease. The frequently cited evidence here is for herbal preparations containing processed leech material in traditional medicine, which is a different thing entirely from applying live leeches. It should not be presented as support for hirudotherapy.
Varicose veins. The available report is small and non-randomised. Varicose vein treatment has a substantial evidence base, and leeches are not part of it.
Detoxification. There is no supporting evidence, and there is no way to generate any, because the claim has no defined endpoint. No specific toxin is named and no measurable outcome is proposed. Saying “more research is needed” would imply a researchable question exists. Detoxification is performed by the liver and kidneys.
One further note: there is no Cochrane systematic review of leech therapy for any indication, which itself indicates the evidence base has not attracted top-tier review attention.
A Caution About Sources
Several websites that rank highly for leech therapy searches are advocacy or commercial operations promoting it for the unevidenced uses above. Some mix accurate regulatory detail with claims about metabolic and hormonal effects that have no support. Accurate detail in one paragraph is not a reason to trust the next one.
If you are considering leech therapy for anything other than post-surgical venous congestion under hospital supervision, ask what evidence exists for your specific condition, and ask where the leeches were sourced.
Leech Therapy FAQs
Is leech therapy FDA approved?
Medicinal leeches were FDA cleared in June 2004, which is a lower bar than approval. The cleared use is relieving venous congestion in healing graft or reattached tissue. No other use is cleared.
What is leech therapy actually used for in hospitals?
Salvaging tissue with venous congestion after reconstructive surgery, replantation, or revascularisation. Ear and finger reattachments and reconstructive flaps are the classic situations.
Does leech therapy work for arthritis?
Trials in knee osteoarthritis show improvement in pain and function, but the total sample across all randomised trials is about 264 patients, blinding is impossible, and adverse events were higher. It is preliminary, not established, and it is not a cleared use.
Is leech therapy dangerous?
It carries real risks. Infection from Aeromonas bacteria that live in the leech gut is the main one, requiring preventive antibiotics, with drug-resistant cases now reported. Significant blood loss and transfusion are common in hospital use.
Can I buy leeches and do this at home?
No. Clinical leeches are prescription medical devices from cleared suppliers. Wild or bait-shop leeches carry unknown bacteria and residual blood from a previous host, which is a direct infection route. Hospital use also involves antibiotic cover and blood monitoring.
Does leech therapy detoxify the blood?
There is no evidence for this and no defined mechanism. Detoxification is carried out by the liver and kidneys.
